H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of ...

Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide ...

Leerink Partnrs issued their Q1 2025 earnings per share estimates for Mind Medicine (MindMed) in a report released on ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

Rad AI, one of the fastest growing healthcare AI companies and the first to successfully commercialize a generative AI ...

REGENXBIO Inc. today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

Evercore ISI initiated coverage on MindMed shares (NASDAQ:MNMD) with an Outperform rating and a price target of $23.00, well ...

Truist Securities analyst Peter Osterland initiated coverage on Westlake Corporation WLK with a Buy rating and announced a ...